A study in humans demonstrated that the mir-362 was significantly upregulated in serum from patients with mild traumatic brain injury (mTBI) at baseline compared to controls, with expression progressively reducing at 24 and 48 hours post-injury, and it was also differentially expressed between mTBI patients and those with other injuries, identifying it as a sensitive and specific biomarker for monitoring the post-trauma period [Polito et al. DOI:10.1007/s11033-020-05386-7]. In a separate pilot study using a Göttingen minipig model of lethal total body irradiation, the mir-362 was identified as an early marker, being consistently down-regulated in plasma across all post-irradiation phases [Chakraborty et al. DOI:10.1038/s41598-023-45250-9].